NZ269411A - Hydrogel microencapsulated vaccines containing antigens - Google Patents
Hydrogel microencapsulated vaccines containing antigensInfo
- Publication number
- NZ269411A NZ269411A NZ269411A NZ26941194A NZ269411A NZ 269411 A NZ269411 A NZ 269411A NZ 269411 A NZ269411 A NZ 269411A NZ 26941194 A NZ26941194 A NZ 26941194A NZ 269411 A NZ269411 A NZ 269411A
- Authority
- NZ
- New Zealand
- Prior art keywords
- poly
- polymer
- antigen
- aliphatic
- group
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 139
- 102000036639 antigens Human genes 0.000 title claims abstract description 138
- 108091007433 antigens Proteins 0.000 title claims abstract description 138
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 239000000017 hydrogel Substances 0.000 title claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 119
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 239000011859 microparticle Substances 0.000 claims abstract description 27
- 238000004132 cross linking Methods 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 230000009851 immunogenic response Effects 0.000 claims abstract description 6
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract 4
- 239000004005 microsphere Substances 0.000 claims description 125
- -1 poly(acrylamide) Polymers 0.000 claims description 103
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 84
- 235000010443 alginic acid Nutrition 0.000 claims description 68
- 229920000615 alginic acid Polymers 0.000 claims description 68
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical group O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 67
- 229940072056 alginate Drugs 0.000 claims description 67
- 206010022000 influenza Diseases 0.000 claims description 63
- 239000002671 adjuvant Substances 0.000 claims description 38
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 30
- 102000009016 Cholera Toxin Human genes 0.000 claims description 28
- 108010049048 Cholera Toxin Proteins 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 229920000867 polyelectrolyte Polymers 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 230000028993 immune response Effects 0.000 claims description 23
- 125000001931 aliphatic group Chemical group 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 19
- 238000006460 hydrolysis reaction Methods 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000015556 catabolic process Effects 0.000 claims description 10
- 150000001768 cations Chemical class 0.000 claims description 10
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 125000004986 diarylamino group Chemical group 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 claims description 4
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 229920000768 polyamine Polymers 0.000 claims description 4
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 208000005647 Mumps Diseases 0.000 claims description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 3
- 208000000474 Poliomyelitis Diseases 0.000 claims description 3
- 241000702670 Rotavirus Species 0.000 claims description 3
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 3
- 208000005252 hepatitis A Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 208000010805 mumps infectious disease Diseases 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 201000005404 rubella Diseases 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 101710082714 Exotoxin A Proteins 0.000 claims description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims description 2
- 241000193449 Clostridium tetani Species 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 2
- 206010013023 diphtheria Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 241000186216 Corynebacterium Species 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000003053 immunization Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 230000036039 immunity Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 229920003169 water-soluble polymer Polymers 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 10
- 230000009885 systemic effect Effects 0.000 description 10
- 229940037003 alum Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000003628 erosive effect Effects 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 239000003094 microcapsule Substances 0.000 description 9
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229920002521 macromolecule Polymers 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000003362 replicative effect Effects 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 230000000240 adjuvant effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000003563 lymphoid tissue Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920002632 poly(dichlorophosphazene) polymer Polymers 0.000 description 5
- 230000002516 postimmunization Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 102100029173 Choline-phosphate cytidylyltransferase B Human genes 0.000 description 2
- 101710100756 Choline-phosphate cytidylyltransferase B Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000000285 follicular dendritic cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036433 growing body Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008239 natural water Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000028241 peripheral precocious puberty Diseases 0.000 description 2
- 210000001986 peyer's patch Anatomy 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 238000002962 plaque-reduction assay Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- 229940124931 vaccine adjuvant Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- JIDDDPVQQUHACU-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbaldehyde Chemical group O=C[C@@H]1CCCN1 JIDDDPVQQUHACU-YFKPBYRVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GIUTUZDGHNZVIA-UHFFFAOYSA-N 2-(ethylamino)acetic acid;hydrochloride Chemical compound Cl.CCNCC(O)=O GIUTUZDGHNZVIA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- RDFLLVCQYHQOBU-GPGGJFNDSA-O Cyanin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO)O1)c1c(-c2cc(O)c(O)cc2)[o+]c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O3)cc(O)c2)c1 RDFLLVCQYHQOBU-GPGGJFNDSA-O 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 125000000254 aspartoyl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000017168 chlorine Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- RDFLLVCQYHQOBU-ZOTFFYTFSA-O cyanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=[O+]C1=CC(O)=C2)C=3C=C(O)C(O)=CC=3)=CC1=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RDFLLVCQYHQOBU-ZOTFFYTFSA-O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 210000005205 gut mucosa Anatomy 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000583 toxicological profile Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000005454 tryptophanyl group Chemical group 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
- C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
- C08G79/025—Polyphosphazenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Provided are vaccine compositions comprising hydrogel microparticles formed of one or more biocompatible polymers encapsulating an amount of an antigen effective to elicit an immunogenic response, wherein the microparticles have a diameter of 200 microns or less. Suitable polymers are selected from polymers and salts thereof that can be crosslinked by physical crosslinking, convalent crosslinking or ionic crosslinking to for a hydrogel. The compositions can be used to deliver the antigen to mucosal surfaces.
Description
P:\UV\VRI015 269411 HYDROGEL MICROENCAPSULATED VACCINES Background of the Invention The present invention is a microsphere configured vaccine vehicle based on a water soluble polymer or hydrogel.
This is a continuation in part of US Patent No. 5494673 which was granted on 27 February 1996.
Induction of an Immune Response via Mucosal Surfaces The majority of virus utilize mucosal surfaces as the primary site of infection. Depending on the virus, the infection either remains localized to the mucosal surface or disseminates to establish a systemic infection. Examples of viruses eliciting local infections are influenza, parainfluenza and common cold viruses which propagate in the respiratory mucosa and rotavirus and the Norwalk agent that replicate in the intestinal mucosa. Viruses that induce systemic viral infections that spread from the mucosa are exemplified by measles, mumps, rubella, polio, hepatitis A and B and herpes viruses.
During the last few years a great deal of information has accrued on the induction of mucosal immunity. In the gut, for example, the immune response is localized to the Peyer's patches embedded in the gut mucosa. Lymphoid tissue at these locations is exposed to the lumen of the gut (gut associated WO 95/02416 PCT/US94/07749 lymphoid tissue, GALT), permitting a constant sampling of the luminal contents. Similar lymphoid tissue called the bronchiolar associated lymphoid tissue (BALT) is located in the respiratory mucosa.
Currently, the majority of viral vaccines establish a state of systemic protective immunity following injection of live attenuated or inactivated virus preparations. The success of such vaccines is due to the induction of a cell mediated and/or humoral immune response in the vaccinee. This systemic immunity prevents the onset of disease by reducing viral replication at the mucosa and eliminating the spread of the virus to important target organs.
The use of injectable vaccines has dramatically reduced the incidence of many viral diseases. Nevertheless, their usage is associated with some undesirable effects. Live attenuated virus vaccines can cause systemic complications whereas inactivated vaccines can cause local reactions and even induce an allergic state. Two important consequences of these vaccine side effects are low compliance and litigation. The former leads to reduced immunity and increased rates of natural infection whereas anfche latter impedes the improvement of current vaccines development of new vaccines.
An alternative to the use of injectable vaccines is the oral administration of antigen, especially of a live attenuated virus. Such a vaccine induces both a strong mucosal and systemic immunity mimicking the immune response induced by natural infection with the wild type virus. This constellation of immune responses eliminates not only the systemic spread of virus but also viral replication in the mucosa. Thus, the immune response elicited by a replicating oral vaccine is superior to that induced by injectable live or inactivated vaccines. The best example of this type of vaccine is the live attenuated oral polio virus vaccine (OPV). Unfortunately, oral administration of live virus is limited to those viruses which survive passage through the stomach and which do not easily revert to virulence.
SUBSTITUTE SHEET (RULE 25) WO 95/02416 PCT/US94/07749 The most effective non-replicating antiviral vaccines thus far developed have been inactivated virus particles. The efficacy of peptide and subunit vaccines in animal models has had limited success and currently there are no human vaccines using these kinds of formulations. In the early years of recombinant DNA engineering, many groups fully expected not only the development of protective immunity but also resolution of safety issues by producing non-infectious viral antigens.
Unfortunately, it has become increasingly clear that there is no reason to assume that a viral protein produced in a laboratory expression vector, highly purified and injected into a vaccinee will assume a conformation in vivo which even remotely approximates the antigenic state found in natural infection. To date, the only successful recombinant derived vaccine has been the hepatitis B surface (HBS) antigen synthesized in an eucaryotic (yeast) expression system.
There is a growing body of evidence demonstrating that oral presentation of non-replicating antigens in the particulate state induces both a mucosal and systemic immunity that closely mimics the immunity induced by natural infection. This is in contrast to oral immunization with non-replicating soluble antigens which not only fail to induce systemic immunity but very often induce a state of systemic tolerance. Furthermore, the antigen doses required to elicit this immunity are far lower than that required for parenteral immunization with the same antigen. The major advantages inherent in such a vaccine formulation are the ease of administration and complete safety.
SUBSTITUTE SHEET (RULE 26) WO 95/02416 PCT/US94/07749 Adjuvants The advent of modern molecular biology has provided a means of producing immunogens with unprecedented ease and precision. It is ironic that these new methodologies generate purified immunogens that do not generally induce a strong immune response in the absence of an effective adjuvant. The development of improved vaccine adjuvants for use in humans has therefore become a priority area of research. Nevertheless, research on adjuvants has lagged seriously behind the work done on immunogens. For decades the only adjuvant widely used in humans has been alum. Saponin and its purified component Quil A, Freund's complete adjuvant and other adjuvants used in research and veterinary applications have toxicities which limit their potential use in human vaccines. New chemically defined preparations such as muramyl dipeptide and monophosphoryl lipid A are being studied.
The traditional view on how adjuvants exert their effect is that adjuvants such as mineral oil emulsions or aluminum hydroxide form an antigen depot at the site of injection that slowly releases antigen. However, excision of the injection site after three days was found to have little effect on immune responses. Recent studies indicate that adjuvants enhance the immune response by stimulating specific and sometimes very narrow arms of the immune response by the release of cytokines, as reviewed by A.C. Allison and N.E. Byars, in: "Vaccines: New Approaches to Immunological Problems", R.W. Ellis, ed., p. 431 (Butterworth-Heinemann, Oxford 1992). It is desirable to have an adjuvant that would act as a simple depot for the release of antigens over an extended period.
An area of adjuvant research that has developed over the last few years is the utilization of synthetic polymers in the formulation of a vaccine. The non-ionic block co-polymer surfactants of Hunter, R.L. Topics in vaccine adjuvant research. D.R. Spriggs and W.C. Koff (Eds), pp. 89-98 (CRC Press, 1991) with molecular weights below approximately 10,000, have a simple SUBSTITUTE SHEET (RULE 26) - structure composed of two blocks of hydrophilic polyoxyethylene (POE) flanking a single block of hydrophobic polyoxypropylene (POP). They are considered to be among the least toxic of surfactants and are widely used in foods, drugs and cosmetics. Some of the large hydrophobic co-polymers are effective adjuvants while closely related preparations are not. There is a correlation between the adjuvant activity of these copolymers with differences in the chain links of the POE and POP.
Currently, these adjuvants are used in an oil and water emulsion.
A wide range of polyelectrolytes of various molecular weights have also been shown by Petrov, et al. Sov. Med. Rev. Section D Immunology, 4:1-113 (1992), to have an adjuvant activity. Macromolecules bearing either positive or negative charges have displayed a similar immunostimulatory activity. The polyelectrolytes form complexes with antigens through electrostatic and hydrophobic bonds. On the other hand, neutral and uncharged polymers had no effect on the immune response.
Controlled Release of Drugs and Antigens There is currently considerable interest in the development of controlled release vaccines, since the major disadvantage of several currently available vaccines is the need for repeated administrations. Controlled release vaccines could obviate the need for booster immunizations, which would be particularly advantageous in developing countries, where repeated contact between the healthcare worker and the vaccine recipient is often difficult to achieve. There is a growing body of evidence showing that antigen persisting on the external membrane of follicular dendritic cells and lymph node organs is involved in the recruitment of B memory cells to form antibody secreting cells. The continual release of circulating antibodies suggests this recruitment happens continually. As the level of antigen decreases this allows the well established phenomena of affinity maturation of antibody to occur. Acceptance of the antigen persistence concept has an important implication in vaccine development. Ideally, it would be advantageous to be able to SUBSTITUTE SHEET (RULE 26) 6- formulate vaccines in a way such that antigen is presented to the immune system and, in particular, the follicular dendritic cells, over an extended period of time.
A number of polymers have been used to entrap antigens, as well as other proteins and compounds. An early example of this is the polymerization of influenza antigen within methyl methacrylate spheres having diameters less than one micron (1,000 nanometers) to form so-called nano particles, reported by Kreuter, J. Microcapsules and Nanoparticles in Medicine and Pharmacology. M. Donbrow (Ed)., p. 125-148 (CRC Press). The antibody response as well as the protection against infection with influenza virus was significantly better than when antigen was administered in combination with aluminum hydroxide. Experiments with other particles demonstrated that the adjuvant effect of these polymers depends on particle size and hydrophobicity.
Several factors contribute to the selection of a particular polymer for microencapsulation. The reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered.
Biodegradable polymers may be designed around one of many types of labile bonds. Examples are polycarbonates, polyesters, polyurethanes, polyorthoesters and polyamides. One of the advantages of using a synthetic polymer for microencapsulation, rather than a naturally occurring polymer, is that the relative rates of hydrolysis of these bonds under neutral conditions can be influenced by the substituents to the polymer backbone. Substituent modification can also be used to alter the solubility and hydrophilicity/hydrophobicity of the polymer.
A frequent choice of a carrier for pharmaceuticals and more recently for antigens, is poly (D,L-lactide-co-glycolide) SUBSTITUTE SHEET (RULE 26) (PLGA). Acceptability by the regulatory authorities remains a significant obstacle for any antigen delivery system. PLGA polymers are biodegradable and biocompatible polyesters which have been used as resorbable sutures for many years, as reviewed by Eldridge, J.H., et al. Current Topics in Microbiology and Immunology. 1989, 146: 59-66. The entrapment of antigens in PLGA microspheres of 1 to 10 microns in diameter has been shown to have an adjuvant effect.
A major disadvantage of the PLGA system is the use of organic solvents and long preparation times for the microencapsulation of the antigens. The process utilizes a phase separation of a water-in-oil emulsion. The compound of interest is prepared as an aqueous solution and the PLGA is dissolved in a suitable organic solvents such as methylene chloride and ethyl acetate. These two immiscible solutions are coemulsified by high-speed stirring. A nonsolvent for the polymer is then added, causing precipitation of the polymer around the aqueous droplets to form embryonic microcapsules. The microcapsules are collected, and stabilized with a polyelectrolyte such as polyvinyl alcohol (PVA), gelatin, alginate, polyvinylpyrrolidone (PVP), or methyl cellulose, and the solvent removed by either drying in vacuo or solvent extraction. While these preparation conditions have been used successfully for microencapsulation of a variety of peptide drugs and hardy immunogens such as staphylococcal enterotoxin B and keyhole limpet cyanin, as demonstrated by J.H. Eldridge, et al., Infection and Immunity 9:2978 (1991), the high shear forces, the use of organic solvents and the long preparation times needed for microencapsulation using PLGA could be detrimental to important epitopes on complex labile immunogens such as enveloped viruses.
It is therefore an object of the present invention to provide materials for encapsulation and delivery by parenteral or mucosal administration of vaccines which do not require the use of organic solvents or long preparation times;and/or INTELLECTUAL PROPERTY OFFICE OF N.Z. - 5 FEB 2001 DECEIVED to provide a system for delivery of antigen to mucosal surfaces, especially through oral delivery; and/or —' - ' > to provide a delivery system for delivery of antigens which elicits a broad spectrum of immunogenic responses; and/or to provide a delivery system for delivery of vaccines which enhances the immunogenicity of the vaccines; and/or to provide a biodegradable delivery system providing controlled release of antigen.
Summary of the Invention Water soluble polymers and polymeric hydrogels are used to microencapsulate antigen for delivery to mucosal surfaces and for the controlled release of antigen at the mucosal surface, or for injection (parenteral administration). In the most preferred embodiment, the encapsulated antigen is administered orally or intranasally. The polymer can be any biocompatible, crosslinkable water-soluble polymer or polymeric hydrogel which can be used to form a microparticle having a diameter of two hundred microns or less, under conditions which are gentle and do not denature the antigen to be incorporated therein. Preferred natural water soluble polymers include alginate, gelatin, pectin, and collagen; preferred synthetic water soluble polymers include poly(acrylamide), poly(methacrylamide), poly(vinyl acetate), poly(N-vinyl pyrrolidone), poly(hydroxyethylmethacrylate), poly(ethylene glycol), polyvinylamines, poly(vinylpyridine), phosphazene polyelectrolytes, and poly(vinyl alcohols); preferred polymers forming hydrogels by ionic crosslinking include salts of poly(acrylic acids) or poly(methacrylic acid), sulfonated polystyrene, quaternary salts of either polyamines or poly(vinylpyridine); and mixtures and copolymers of the polymers INTELLECTUAL PROPERTY OFFICE OF N.Z. ~ 5 FEB 2001 J RECEIVES * ;PCX /US94/07749 ;9- ;or monomers thereof. The most preferred polymers are alginate, polyphosphazenes, and mixtures thereof. ;To prepare the encapsulated antigen, the antigen is mixed with a polymer solution, microparticles are rapidly formed of the polymer and antigen without the use of significant quantities of organic solvents, and the polymer is crosslinked ionically or covalently to form a stable biodegradable microparticle. The microparticles adhere to mucosal surfaces such as the mucosal lining of the gastrointestinal tract, increasing takeup by the reticuloendothelium of antigen as it is released over time. The polymers are preferably alginate or a polyphosphazene, most preferably crosslinked ionically with a polyion or divalent cation, such as calcium chloride. ;Examples demonstrate the enhanced immunogenicity of polymer encapsulated antigen, alone or in combination with a mucosal stimulant such as cholera toxin, as well as how to manipulate the polymers to alter release rates and humoral response, when administered parenterally, orally, or intranasally. ;Brief Description of the Drawings ;Figure 1 is a graph of the permeability of polyphosphazene microspheres, measured as percent release as a function of encapsulated protein molecular weight and polymer concentration. Rainbow protein markers were microencapsulated in three concentrations of poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazen e] (PP): 3.3% (dotted bars), 2.5% (hatched bars), and 1.5% (dark bars), and incubated in HEPES buffer pH 7.4 at room temperature for 24 hours before the amount of protein in the supernatant was spectrophotometrically measured. ;Figure 2 is a graph of the effect of molecular weight on erosion profiles of polyphosphazene microspheres, measured as percent mass loss over time in days: PC-GIP, 130 KDa (squares); ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;10- ;PCPP, 3900 KDa (diamonds); PC-GIP, 170 KDa (circles); and PCPP, 400 KDa (triangles). ;Figures 3a and 3b are molecular weight degradation profiles over time in days for PCPP hydrogels with different starting molecular weights of polyphosphazenes: Mw, molecular weight, Mn, number average molecular weight, initial Mw 3,900 KDa (Figure 3a), and Mw 400 KDa (Figure 3b). ;Figure 4 is a molecular weight degradation profile over time in days for PC-GIPP hydrogel for Mw 17 0 KDa, comparing molecular weight of polymer in the matrix with molecular weight of polymers in solution. ;Figure 5 is a graph of percent release of polystyrene beads from polyphosphazene microspheres coated with poly-L-lysines of different molecular weights: 12,000 mw (squares), 62,500 mw (diamonds), 140,800 mw (circles), and 295,000 mw (triangles). Fluorescent polystyrene (PS) beads measuring 20 nm in diameter were encapsulated in polymer 1 and then coated with poly-L-lysines of different molecular weights. The coated beads were incubated in HEPES buffer pH 7.4 at room temperature. Polystyrene beads released into the supernatant were measured by quantitative fluorimetry and expressed as a percent of the initially encapsulated beads. ;Figures 6a, 6b, and 6c are graphs of the flu-specific responses in the sera of animals immunized with flu virus in suspension (Figure 6a), encapsulated flu virus in combination with cholera toxin (CT) in alginate microspheres (Figure 6b), and flu virus encapsulated in alginate microspheres (Figure 6c), measured as antibody titer (reading left to right: IgM, dark bars; IgG, hatched bars; IgA, stipled bars) at 7, 14, 21, and 28 days. ;Figure 7 is the flu specific antibody response in the sera following oral administration of influenza encapsulated in alginate in combination with CT, measured at seven, 14, 21, 28, and 35 days post immunization, for IgM, dark bars; IgG, hatched bars; IgA, stipled bars. ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;11- ;Figure 8 is a graph of the flu-specific antibody response in the fecal samples following administration orally of influenza in alginate microcapsules in combination with CT, following an oral boost, measured at seven, 14, 21, 28 and 35 days after the boost, for IgM, dark bars; IgG, hatched bars; IgA, stipled bars. ;Detailed Description of the Invention ;In general, microspheres for delivery of antigen are formed by covalent or ionic crosslinking of water soluble polymers or polymers that form hydrogels. In the preferred embodiment, the polymers are formed of water soluble polymers such as alginate or polyphosphazenes which are ionically crosslinked with divalent cations such as calcium ions to form a water-insoluble hydrogel encapsulating antigen. Antigen is mixed with the polymer solution prior to crosslinking to insure dispersion of the antigen throughout the microsphere. More stable microspheres can be formed by further crosslinking the microspheres with a polyelectrolyte such as a polyamino acid. ;Polymers useful for making Microspheres. ;The polymer can be almost any biocompatible, crosslinkable water-soluble polymer or polymeric hydrogel which can be used to form a microparticle having a diameter of ten microns or less, under conditions which are gentle and do not denature the antigen to be incorporated therein. As used herein, a hydrogel is defined as any water-swollen polymer. Water-soluble polymers are those that are at least partially soluble (typically to an extent of at least 0.001% by weight) in water, an aqueous buffered salt solution, or aqueous alcohol solution. Preferred natural water soluble polymers include alginate, gelatin, pectin, and collagen; preferred synthetic water soluble polymers include poly(aerylamide), poly(methacrylamide), poly(vinyl acetate), poly(N-vinyl pyrrolidone), poly(hydroxyethylmethacrylate), poly(ethylene glycol), ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;-12- ;polyvinylamines, poly(vinylpyridine), phosphazene polyelectrolytes, and poly(vinyl alcohols); preferred polymers forming hydrogels by ionic crosslinking include poly(acrylic acids) or poly(methacrylic acid), sulfonated polystyrene, quaternary salts of either polyamines or poly(vinylpyridine); and mixtures and copolymers of the polymers or monomers thereof. The most preferred polymers are alginate, polyphosphazenes, and mixtures thereof. ;The polymers can be crosslinked either by ionic crosslinking, covalent crosslinking or physical crosslinking to render the water-soluble polymers water-insoluble. Gelation by ionic crosslinking of an aqueous based polymer solution at room temperature eliminates the long exposure to organic solvents, elevated temperatures and drying required by polymers dissolved in organic solvents. The polymers can be crosslinked in an aqueous solution containing multivalent ions of the opposite charge to those of the charged side groups, such as multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups. Preferably, the polymers are cross-linked by di and trivalent metal ions such as calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, and iron, or polycations such as poly(amino acid)s, poly(ethyleneimine), poly(vinylamine), poly(vinylpyridine), polysaccharides, and other that can form polyelectrolyte complexes. ;Alginates. ;The best studied ion crosslinkable polymer is the naturally occurring alginate that is prepared from brown algae for use in foodstuffs, for example, Protanal LF 20/60 (Pronova, Inc., Portsmouth, NH, USA). ;The polymer is cross-linked with a multivalent ion, preferably using calcium chloride or other divalent or multivalent cation. ;Polyphosphazenes. ;SUBSTITUTE SHEET (RULE 26) ;PCX /US94/07749 ;13- ;The elucidation of a class of ion cross-linkable water soluble polyphosphazenes, described by H.R. Allcock and S. Kwon., Macromolecules 22, 75-79 (1989), has made it possible to generate microspheres containing antigens that throughout preparation are exposed only to an aqueous environment. ;The term amino acid, as used herein, refers to both natural and synthetic amino acids, and includes, but is not limited to alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaoyl, lysinyl, argininyl, and histidinyl. ;The term amino acid ester refers to the aliphatic, aryl or heteroaromatic carboxylic acid ester of a natural or synthetic amino acid. ;The term alkyl, as used herein, refers to a saturated straight, branched, or cyclic hydrocarbon, or a combination thereof, typically of C, to C20, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, heptyl, octyl, nonyl, and decyl. ;The term (alkyl or dialkyl.) amino refers to an amino group that has one or two alkyl substituents, respectively. ;The terms alkenyl and alkynyl, as used herein, refers to a C2 to C20 straight or branched hydrocarbon with at least one double or triple bond, respectively. ;The term aryl, as used herein, refers to phenyl or substituted phenyl, wherein the substituent is halo, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, alkoxyalkyl, methylenedioxy, cyano, C(0)(lower alkyl), ;-C02H, -S03H, -POjH, -CO,alkyl, amide, amino, alkylamino and dialkylamino, and wherein the aryl group can have up to 3 substituents. ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;14- ;The term aliphatic refers to hydrocarbon, typically of C, to C20, that can contain one or a combination of alkyl, ;alkenyl, or alkynyl moieties, and which can be straight, ;branched, or cyclic, or a combination thereof. ;The term halo, as used herein, includes fluoro, chloro, bromo, and iodo. ;The term aralkyl refers to an aryl group with an alkyl substituent. ;The term alkaryl refers to an alkyl group that has an aryl substituent, including benzyl, substituted benzyl, phenethyl or substituted phenethyl, wherein the substituents are as defined above for aryl groups. ;The term heteroaryl or heteroaromatic, as used herein, refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring, and that can be optionally substituted as described above for aryl groups. Nonlimiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbozolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl,. pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl. ;The term "pharmaceutically acceptable ion" refers to an organic or inorganic moiety that carries a charge and that can be administered as a counterion in a phosphazene polyelectrolyte. ;The term heteroalkyl, as used herein, refers to an alkyl group that includes a heteroatom such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain. ;SUBSTfTOTE SHEET (RULE 26) ;WO 95/02416 ;PCT/US94/07749 ;15- ;The terms poly[(carboxylatophenoxy)(glycinato) phosphazene], poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazen e-co-(carboxylatophenoxy) (glycinato)phosphazene] and poly[di(carboxylatophenoxy) phosphazene-co-di(glycinato)phosphazene] as used herein refer to the same polymer. ;The polyphosphazene preferably contains charged side groups, either in the form of an acid or base that is in equilibrium with its counter ion, or in the form of an ionic salt thereof. ;The polymer is preferably biodegradable and exhibits minimal toxicity when administered to animals, including humans. ;Selection of Phosphazene Polyelectrolytes. ;Polyphosphazenes are polymers with backbones consisting of alternating phosphorus and nitrogen, separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two pendant groups ("R"). The repeat unit in polyphosphazenes has the following general formula: ;wherein n is an integer. ;The substituent ("R") can be any of a wide variety of moieties that can vary within the polymer, including but not limited to aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, carbohydrates, including glucose, heteroalkyl, halogen, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to -oxyphenylC02H, -oxyphenylS03H, ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;-oxyphenylhydroxyl and -oxyphenylP03H; -oxyaliphatic including - ;oxyalkyl, -oxy(aliphatic)C02H, ;-oxy(aliphatic)S03H, -oxy(aliphatic)P03H, and ;-oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxy1; ;-oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic including - ;thioalkyl, -thioalkaryl, -thioaralkyl, ;-NHC(0)0-(aryl or aliphatic), -0-[ (CH2)xO]y-CH2)xNH2, ;-0- [ (CH2) xO ] yCH2) XNH (CH2) xS03H , and ;-0-[ (CH2 )x0]y-(aryl or aliphatic), wherein x is 1-8 and y is an integer of 1 to 20. The groups can be bonded to the phosphorous atom through, for example, an oxygen, sulfur, nitrogen, or carbon atom. ;In general, when the polyphosphazene has more than one type of pendant group, the groups will vary randomly throughout the polymer, and the polyphosphazene is thus a random copolymer. Phosphorous can be bound to two like groups, or two different groups. Polyphosphazenes with two or more types of pendant groups can be produced by reacting poly(dichlorophosphazene) with the desired nucleophile or nucleophiles in a desired ratio. The resulting ratio of pendant groups in the polyphosphazene will be determined by a number of factors, including the ratio of starting materials used to produce the polymer, the temperature at which the nucleophilic substitution reaction is carried out, and the solvent system used. While it is very difficult to determine the exact substitution pattern of the groups in the resulting polymer, the ratio of groups in the polymer can be easily determined by one skilled in the art. ;In one embodiment, the biodegradable polyphosphazene has the formula: ,— ^ ;pr/V ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;17- ;wherein A and B can vary independently in the polymer, and can be: ;(i) a group that is susceptible to hydrolysis under the conditions of use, including but not limited to chlorine, amino acid, amino acid ester (bound through the amino group), ;imidazole, glycerol, or glucosyl; or ;(ii) a group that is not susceptible to hydrolysis under the conditions of use, including, but not limited to an aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, heteroalkyl, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to ;-oxyphenylC02H, -oxyphenylS03H, -oxyphenylhydroxyl and -oxyphenylP03H; -oxyaliphatic including -oxyalkyl, -oxy(aliphatic)C02H, -oxy (aliphatic) S03H, ;-oxy(aliphatic)P03H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxyl; -oxyalkaryl, ;-oxyaralkyl, -thioaryl, -thioaliphatic including -thioalkyl, -thioalkaryl, or thioaralkyl; ;wherein the polymer contains at least one percent or more, preferably 10 percent or more, and more preferably 80 to 90 percent or more, but less than 100%, of repeating units that are not susceptible to hydrolysis under the conditions of use, and wherein n is an integer of 4 or more, and preferably between 10 and 20,000. ;It should be understood that certain groups, such as heteroaromatic groups other than imidazole, hydrolyze at an extremely slow rate under neutral aqueous conditions, such as that found in the blood, and therefore are typically considered nonhydrolyzable groups for purposes herein. However, under certain conditions, for example, low pH, as found, for example, in the stomach, the rate of hydrolysis of normally nonhydrolyzable groups (such as heteroaromatics other than ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;18- ;imidazole) can increase to the point that the biodegradation properties of the polymer can be affected. One of ordinary skill in the art using well known techniques can easily determine whether pendant groups hydrolyze at a significant rate under the conditions of use. One of ordinary skill in the art can also determine the rate of hydrolysis of the polyphosphazenes of diverse structures as described herein, and will be able to select that polyphosphazene that provides the desired biodegradation profile for the targeted use. ;The degree of hydrolytic degradability of the polymer will be a function of the percentage of pendant groups susceptible to hydrolysis and the rate of hydrolysis of the hydrolyzable groups. The hydrolyzable groups are replaced by hydroxyl groups in aqueous environments to provide P-OH bonds that impart hydrolytic instability to the polymer. ;In other embodiments, the polyphosphazene is: (i) a nonbiodegradable polyphosphazene wherein none, or virtually none, of the pendant groups in the polymer are susceptible to hydrolysis under the conditions of use, or (ii) a completely biodegradable polyphosphazene wherein all of the groups are susceptible to hydrolysis under the conditions of use (for example, poly[di(ethylglycinato)-phosphazene]). ;Phosphazene polyelectrolytes are defined herein as polyphosphazenes that contain ionized or ionizable pendant groups that render the polyphosphazene anionic, cationic or amphophilic. The ionic groups can be in the form of a salt, or, alternatively, an acid or base that is or can be at least partially dissociated. Any pharmaceutically acceptable monovalent cation can be used as counterion of the salt, including but not limited to sodium, potassium, and ammonium. The phosphazene polyelectrolytes can also contain non-ionic side groups. The phosphazene polyelectrolyte can be biodegradable or nonbiodegradable under the conditions of use. The ionized or ionizable pendant groups are preferably not susceptible to hydrolysis under the conditions of use. ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;PCT/US94/07749 ;-19- ;A preferred phosphazene polyelectrolyte contains pendant groups that include carboxylic acid, sulfonic acid, or hydroxyl moieties. While the acidic groups are usually on nonhydrolyzable pendant groups, they can alternatively, or in combination, also be positioned on hydrolyzable groups. An example of a phosphazene polyelectrolyte having carboxylic acid groups as side chains is shown in the following formula: ;wherein n is an integer, preferably an integer between 10 and 10,000. This polymer has the chemical name poly[di(carboxylatophenoxy)phosphazene] or, alternatively, poly[bis(carboxylatophenoxy)phosphazene] (PCPP). ;biodegradable. The term biodegradable, as used herein, means a polymer that degrades within a period that is acceptable in the desired application, typically less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 at a temperature of approximately 25°C-37°C. ;poly(organophosphazene) that includes pendant groups that include carboxylic acid moieties that do not hydrolyze under the conditions of use and pendant groups that are susceptible to hydrolysis under the conditions of use. Examples of preferred phosphazene polyelectrolytes with hydrolysis-sensitive groups are poly[di(carboxylatophenoxy)phosphazene-co-di(amino acid)phosphazene-co-(carboxylatophenoxy)(amino acid)phosphazene], specifically including poly[di(carboxylatophenoxy)phosphazene- ;The phosphazene polyelectrolyte is preferably ;Most preferably the polymer is a ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;20- ;co-di(glycinato)phosphazene-co- ;(carboxylatophenoxy)(glycinato)phosphazene], and poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co-(carboxylatophenoxy)(chloro)phosphazene]. ;The toxicity of the polyphosphazene can be determined using cell culture experiments well known to those skilled in the art. For example, toxicity of ;-poly[di(carboxylatophenoxy)phosphazene] was determined in cell culture by coating cell culture dishes with the poly[di(carboxylatophenoxy)phosphazene]. Chicken embryo fibroblasts were then seeded onto the coated petri dishes. Three days after seeding the chicken embryo fibroblasts, the cells had become flattened and spindles formed. Under phase contrast microscopy, mitotic figures were observed. These observations provide evidence of the non-toxicity of poly[di(carboxylatophenoxy)-phosphazene] to replicating cells. ;Crosslinked polyphosphazenes can be prepared by combining a phosphazene polyelectrolyte with a metal multivalent cation such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, or cadmium. ;Synthesis of Phosphazene Polyelectrolytes Polyphosphazenes, including phosphazene polyelectrolytes, can be prepared by a macromolecular nucleophilic substitution reaction of poly(dichlorophosphazene) with a wide range of chemical reagents or mixture of reagents in accordance with methods known to those skilled in the art. Preferably, the phosphazene polyelectrolytes are made by reacting the poly(dichlorophosphazene) with an appropriate nucleophile or nucleophiles that displace chlorine. Desired proportions of hydrolyzable to non-hydrolyzable side chains in the polymer can be obtained by adjusting the quantity of the corresponding nucleophiles that are reacted with poly(dichlorophosphazene) and the reaction conditions as necessary. ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;21- ;For example, poly[(carboxylatophenoxy)-(glycinato)phosphazene] (PC-G1PP) is prepared by the nucleophilic substitution reaction of the chlorine atoms of the poly(dichlorophosphazene) with propyl p-hydroxybenzoate and ethyl glycinate hydrochloride (PC-G1PP synthesis). The poly[(aryloxy)(glycinato)phosphazene] ester thus obtained is then hydrolyzed to the corresponding poly(carboxylic acid). Other polyphosphazenes can be prepared as described by Allcock, H.R.; et al., Inorg. Chem. 11, 2584 (1972); Allcock, H.R.; et al., Macromolecules 16, 715 (1983);Allcock, H.R.; et al., Macromolecules 19,1508 (1986); Allcock, H.R.; et al., ;Biomaterials 19, 500 (1988); Allcock, H.R.; et al.,Macromolecules 21, 1980 (1988); Allcock, H.R.; et al., Inorg. Chem. 21(2), 515-521 (1982); Allcock, H.R.; et al., Macromolecules 22:75-79 (1989); U.S. Patent Nos. 4,440,921, 4,495,174, 4,880,622 to Allcock, H.R.; et al.,; U.S. Patent No. 4,946,938 to Magill, et al., U.S. Patent No. 5,149,543 to Cohen et al., and the publication of Grolleman, et al., J.Controlled Release 3,143 (1986), the teachings of which, and polymers disclosed therein, are incorporated by reference herein. ;Selection of an Antigen ;The antigen can be derived from a cell, bacteria, or virus particle, or portion thereof. As defined herein, antigen may be a protein, peptide, polysaccharide, glycoprotein, glycolipid, nucleic acid, or combination thereof, which elicits an immunogenic response in an animal, for example, a mammal, ;bird, or fish. As defined herein, the immunogenic response can be humoral or cell-mediated. In the event the material to which the immunogenic response is to be directed is poorly antigenic, it may be conjugated to a carrier such as albumin or to a hapten, using standard covalent binding techniques, for example, with one of the several commercially available reagent kits. ;In one embodiment, the polymer is used to deliver nucleic acid which encodes antigen to cells where the nucleic acid is expressed. ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;Examples of preferred antigens include viral proteins such as influenza proteins, human immunodeficiency virus (HIV) proteins, Haemophilus influenza, and hepatitis B proteins, and bacterial proteins and lipopolysaccharides such as gram negative bacterial cell walls and Neisseria gonorrhea proteins. ;Virus infection of cells in culture generates two kinds of virus particles; mature infectious virus and some noninfectious virus-like particles devoid of nucleic acid. It is preferred to use inactivated mature virus particles in oral vaccines in those cases where the virus replicates to a high titer in cell culture. For virus that either cannot be grown in cell culture or that are tumorigenic, one can use recombinant DNA technology to produce non-replicating virus-like particles (VLPs). Using recombinant technology, one can construct viruslike particles that display on their surface protective antigens (pseudotyping) from virus that because of their inherent complexity do not lend themselves to either of the above two approaches. All of the antigens described above are virus particle structural components, however, not all antigens that elicit protective immunity are structural antigens. In those instances where the protective antigen is a non-structural component, one can genetically fuse such antigens to the surface of self-assembling virus-like particles. ;Adjuvants ;In some embodiments it may be desirable to include an adjuvant with the antigen which is encapsulated for mucosal or parenteral delivery. ;Adjuvants for oral administration. ;It is known that oral administration of an admixture of trace amounts of cholera toxin (CT) (either cholera toxin subunit A, cholera toxin subunit B, or both) and a second antigen stimulate a mucosal immunity to the coadministered antigen. Furthermore, there is a dramatic humoral immune response to the second antigen instead of the immune tolerance that is elicited by oral delivery of the antigen alone. Thus, mucosally delivered ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-23- ;PCT/US94/07749 ;CT functions as a powerful immunostimulant or adjuvant of both mucosal and humoral immunity. The mechanism for this adjuvant effect may be due to the ability of CT to specifically bind to the dome cells (or M cells) overlying the Peyer's patches and then to alter the lymphoid cells in a manner that favors immunoresponsiveness to antigens that may or may not normally bind to the dome cells. Recently, the binding function was localized to the non-toxic B subunit of the cholera toxin (CT-B) molecule. It has now been demonstrated that the addition of CT-B to antigens will mimic the immune response elicited by CT to the same antigens. It is therefore frequently preferred to enhance immunogenicity of the orally administered antigen by including CT in the microencapsulated vaccine. ;Adjuvants for parenteral administration. ;Examples of adjuvants include muramyl dipeptides, muramyl tripeptide, cytokines, diphtheria toxin, and exotoxin A. Commercially available adjuvants include QS-21 from Cambridge Biosciences, Worcester, MA, and monophosphoryl lipid A (MPLA) ;from Ribi Immunochem. ;It is also demonstrated herein that polyphosphazenes can also have an adjuvant effect when administered orally or parenterally. In particular, examples demonstrate the enhanced immunogenicity of microspheres formed of 95% alginate and 5% polyphosphazene (PCPP). ;Preparation of an Immunogenic Composition ;The polymer is used to encapsulate the antigen, for example, using the method of U.S. Patent 5,149,543 to Cohen, et al., or U.S. Patent No. 4,352,883 to Lim, et al., the teachings of which are incorporated herein, or by spray drying a solution of polymer and antigen. Alternatively, microspheres containing the antigen and adjuvant can be prepared by simply mixing the components in an aqueous solution, and then coagulating the polymer together with the substance by mechanical forces to form a microparticle. ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;24- ;As used herein, the term "microcapsule" encompasses microparticles, microspheres, and microcapsules unless otherwise stated. In general, those microcapsules which are useful will have a particle diameter of between one and 200 microns, preferably between one and 15 microns for oral administration, and preferably between one and 100 microns for injection, ;although the limiting factor for injection is the needle size. ;In the preferred embodiment, polyphosphazene/antigen solutions are prepared by first dissolving antigen in 1 part 3% Na?C03 with stirring, followed by the addition of PCPP with stirring until dissolved and then slowly adding 3 parts phosphate buffer pH 7.4. The detergent Brij58 is added to the stirring polymer solution at a final concentration of 0.2%. The final concentration of PCPP is 2.5%. Sodium alginate/antigen solutions are prepared by dissolving the appropriate amount of antigen in deionized water. The alginate is then slowly added to the antigen solution so that the final concentration of alginate is 1.25%. Constant stirring, as well as the slow addition of the polymer to the antigen, is necessary in order to obtain a homogeneous solution. ;In the most preferred embodiment for making microspheres for oral delivery, microspheres are generated using a syringe pump at a speed of 150 yl/min to pump the polymer and antigen solution into an atomization nozzle (Turbotak, Ottawa Canada), or an ultrasonic spray nozzle (Medsonic, Inc., Farmingdale, NY), equipped with an 18 gauge blunt-end needle. The needle enables the solution to be delivered directly to the point of atomization in the nozzle. The polymer solution containing dispersed antigens is then forced through a 1.0 mm orifice in the nozzle under approximately 35 pounds per square inch of air pressure. For polyphosphazenes, the microdroplets cross-link when they impact a 7.5% CaCl2 0.5% Brij58 bath at a distance 35 cm from the nozzle. The Brij58 is added in order to prevent agglomeration of the microspheres. A 1.5% CaCl2 bath (no ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-25- ;PCT/US94/07749 ;Brij58) is used for gelation of alginate microspheres. The microspheres are then quickly transferred to a centrifuge tube and rocked gently for approximately 30 minutes to complete the cross-linking process and to avoid microsphere aggregation as they settle out of the CaCl2 bath. Aggregation may be due to Ca++ crosslinking between exposed carboxylic groups on the microsphere surface and/or hydrophobic interactions between microspheres. After 30 minutes, the microspheres are collected by centrifugation at 4°C, 2800 rpm for 15 minutes. The supernatant is discarded, the pellet is both washed one time and resuspended in sterile deionized water. The microspheres are stored at 4°C until analysis. Approximately 90% of polyphosphazene microspheres generated under these conditions had diameters in the one to ten micron range. ;Larger microspheres are made by using a larger orifice and lower air pressure. ;Polymer-Antigen Conjugates ;The polymer can also be covalently conjugated with the antigen to create a water-soluble conjugate in accordance with methods well-known to those skilled in the art, usually by covalent linkage between an amino or carboxyl group on the antigen and one of the ionizable side groups on the polymer. ;Administration of Immunogenic Composition ;Hydrogel microspheres containing antigen can be administered mucosally or parenterally. Non'limiting examples of routes of delivery to mucosal surfaces are intranasal (or generally, the nasal associated lymphoid tissue), respiratory, vaginal, and rectal. Nonlimiting examples of parenteral delivery include intradermal, subcutaneous, and intramuscular. ;Antigens can be encapsulated in both naturally occurring alginate and synthetic polyphosphazenes. The level of antigen loading, release kinetics and the microsphere size distribution are used to vary the resulting immune response. The dosage is determined by the antigen loading and by standard ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-26- ;PCT/US94/07749 ;techniques for determining dosage and schedules for administration for each antigen, based on titer of antibody elicited by the polymer-antigen administration, as demonstrated by the following examples. ;It will be understood by those skilled in the art that the immunogenic vaccine composition can contain other physiologically acceptable ingredients such as water, saline or a mineral oil such as Drakeol™, Markol™, and squalene, to form an emulsion, or in combination with aqueous buffers, or encapsulated within a capsule or enteric coating to protect the microcapsules from degradation while passing through the stomach. ;Storage of Immunogenic Compositions ;Ionically cross-linked microspheres need to be stored in buffers that are conducive to the maintenance of their integrity. Conditions have been defined that maintain the integrity of the microspheres as well as antigens entrapped within the polymer matrix. Microspheres containing antigen are stable for seven days stored at 4°C in sterile deionized water. Standard buffers such as phosphate buffered saline (PBS) cannot be used because the replacement of calcium ions with sodium leads to the liquification of the matrix. Coating the microspheres with an amino acid polymer such as poly L-lysine or other crosslinking agent allows storage in PBS. ;The present invention will be further understood by reference to the following non-limiting examples. ;Example 1: Toxicity Studies. ;Alginate is approved for human consumption. The polyphosphazenes can be tested to demonstrate non-toxicity using standard methodology. Polyphosphazenes have previously been demonstrated to be non-toxic to living cells. As reported by M.C. Bano, et al., Bio/Technology, 9:468 (1991), hybridoma cells were encapsulated in polyphosphazene microspheres having a diameter between 150 and 200 microns. The encapsulated hybridoma cells were able to undergo cell divisions, and by ten days after ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-27- ;PCT/US94/07749 ;encapsulation the microspheres were essentially filled with living cells. Additional studies are described herein. ;In the first study, cell culture dishes were coated with the polyphosphazene and then chicken embryo fibroblasts seeded onto the coated petri dish. Three days after seeding the chicken embryo fibroblasts, the cells had become flattened and spindle formed and under phase contrast microscopy one could see mitotic figures. This demonstrated the innocuous nature of the polyphosphazenes in cell culture. ;In a second in vivo toxicity study, the in vivo acute toxicity of alginate and polyphosphazene was evaluated in 6-8 week old Sprague-Dawley rats. The study consisted of four groups of five male rats/group. Following an overnight fast, each animal in each group received a single oral dose of 5000 mg polymer/kg (in water) via gavage. The dose volume was 20 ml/kg. Group one rats received water and served as a control group. ;Group two animals received alginate microspheres. Group three rats received alginate microspheres coated with poly-L-lysine (M.W. 68,000). Group four animals received poly[di(carboxylatophenoxy)phosphazene] microspheres. The animals were clinically observed for 7 days. Body weights were recorded on day 1 prior to immunization and at euthanasia. Blood samples were obtained by puncture of the retro-orbital sinus after anesthetization with C02 at euthanasia. Animals were food fasted overnight prior to blood collection. Tissues were examined and saved at necropsy. ;There were no significant differences in body weight gain between the rats that received microspheres and the rats in the control group. The results of hematology and clinical chemistry were normal for all rats in each group. There were no treatment related abnormalities observed in any organ at necropsy. This study demonstrated that at an oral dose of 5000 mg/kg, polyphosphazene and alginate microspheres are not acutely toxic. ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-28- ;PCT/US94/07749 ;Example 2: Incorporation of Proteins and Release ;Characteristics of microspheres. ;In order for the microencapsulated antigens to elicit an immune response, the antigen must be released from the microspheres. Antigen is released from a microsphere through the two different but not mutually exclusive processes of diffusion and erosion. If the hydrogel is permeable to the dispersed antigens, then the antigens can simply diffuse out of the microspheres following the water phase that fills the matrix of the microsphere. Release of antigen is, therefore, an indication of the permeability of the microsphere matrix to the antigen. Conversely, adsorption of the antigens to the polymer matrix will serve to either reduce or eliminate the diffusion of the antigen out of the microsphere. ;Characterization of release kinetics. Protein molecular weight markers (Amersham) and FITC-labelled bovine serum albumin (Sigma) were microencapsulated to study release kinetics of soluble proteins. The release kinetics of 20 nm polystyrene beads (Duke Scientific) can be used for comparative purposes. ;Quantitation of Protein in Microspheres. For immunogenicity studies, the protein content of microspheres is determined both directly after generation of the microspheres to assess the percent incorporation and also immediately before injection into animals to insure delivery of known antigen quantities. ;The protein content of the microspheres can not be assessed by a standard assay such as the Bio-Rad protein assay. Although the protein can be released from the microspheres by chelating the Ca++ responsible for forming the hydrogel, the addition of the Bio-Rad reagent which contains divalent cations causes the polymer to re-cross-link, rendering the antigen unavailable to the dye reagent. ;The quantitation of protein antigens encapsulated in ionically cross-linked microspheres is determined by ;WO 95/02416 ;-29- ;PCT/US94/07749 ;electrophoresing a known quantity of intact microspheres in SDS-PAGE. During electrophoresis, the proteins migrate out of the microsphere matrix and into the polyacrylamide gel. The protein concentration is determined by comparison to known quantities of the encapsulated protein electrophoresed in parallel to the microsphere preparation. ;Determination of Microsphere Size. One to fifteen micron microspheres are believed to have an adjuvant effect and are therefore preferred. The size of alginate and polyphosphazene microspheres is measured utilizing a Coulter LS100 Particle sizer. The size is reported as % number in the one to ten micron size range. ;Modification of antigen release from polyphosphazene microspheres. _ ;Effect of polymer concentration and molecular weight of the antigen. ;The permeability of the poly[di(carboxylatophenoxy) phosphazenes] was investigated by encapsulating protein molecular weight markers (Rainbow™ protein molecular markers (Amersham Corporation), ranging in molecular weight from 14,000 to 200,000 daltons, that are commonly used in polyacrylamide gel electrophoresis. Release of the proteins was assayed by spectrophotometry measurements of the supernatant. ;The results are shown in Figure 1. The permeability of a particular protein such as the 14.3 KDa molecular weight lysozyme was affected by the concentration of the polymer in the gel. As the polymer concentration rises from 1.5% to 3.3% there is a marked decrease in the diffusion of the protein out of the microcapsule matrix. Similarly, as the molecular weight of the protein increases, diffusion of the protein out of the matrix is retarded. For example, the 200 KDa molecular weight myoglobin protein was unable to diffuse out of a 3.3% polyphosphazene matrix in a time period of 24 hours. ;Effect of polymer molecular weight and composition. ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;30- ;The second mechanism by which the antigens can be released from microspheres is through the erosion of the polymer matrix making up the microsphere. Erosion can occur through the reversal of the gelation reaction, resulting in the solubilization of polymer molecules and their return to the surrounding aqueous environment. Degradation of polyphosphazene microspheres was studied in saline solution (pH 7.4) by monitoring mass loss, molecular weights of polymer matrices and formation of soluble products. Erosion profiles for PCPP microspheres of varied molecular weights are shown in Figure 2. No detectable mass loss was observed during 20 days incubation of high molecular weight PCPP microspheres in solution, and for the period of time extended to 180 days. However GPC data show significant decrease in polymer molecular weight during the same period of time (Figure 3a). The mechanism of degradation apparently can involve intramolecular carboxylic group catalysis. Use of low molecular weight PCPP for microsphere preparation leads to significant erosion of the hydrogel during the first 10 days and a decrease in molecular weight of polymer (Figure 3b). Water-soluble polymeric products of practically the same molecular weight as in the matrix were detected. ;These data indicate that there is a molecular weight threshold of approximately 200 KDa in the release of polyphosphazene from the matrix into the solution in this system. However, polymer solubility also depends on the amount of calcium ions (or other multivalent cations or polymers) held by the matrix and the ionization degree of macromolecules. The observed differences in the erosion of PCPP are of prime importance for the design of antigen delivery systems. ;Polyphosphazenes can be efficiently tailored by incorporating appropriate side-groups to provide a controllable set of properties, including hydrolytic degradability. Introduction of a hydrolysis-sensitive pendant group, such as glycinato group, increases the degradation rate in an aqueous environment. Cleavage of an external P-N bond occurring in ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-31- ;PCT/US94/07749 ;neutral media in these aminophosphazenes to yield hydroxy derivatives confers hydrolytic instability in the polymer. ;Poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato) phosphazene] (PC-G1PP) containing 10% of glycinato groups was used for the preparation of microspheres and degradation studies. Erosion rates for these polymer hydrogels also depend on the molecular weight of polyphosphazenes. PC-GIPP with weight average molecular weight 130 KDa has a 100% mass loss within 3 days, as shown by Figure 2. The GPC analysis of matrix and soluble products shows in Figure 4 that a 240 day incubation in an aqueous environment results in breakdown of the polymer backbone leading to fragments with molecular weights lower than 1 KDa and inorganic phosphate. Coating hydrogel microspheres with Poly-L-lysine (M.W. 62 KDa) to yield a polyelectrolyte complex membrane significantly decreases the erosion rate by 2.5 times apparently because of steric hindrances, providing an additional approach to control the degradation and stability of polyphosphazene microspheres. ;Effect of Crosslinking agents. ;The third means by which one can regulate the release of antigen from microspheres is by coating the polyphosphazene microspheres with poly-L-lysine or a similar polyion to form a semi-permeable membrane on the outside of the microspheres. The microsphere core can then be liquified by the addition of chelating agents such as EDTA which reverse the gelation process and result in the solubilization of the polyphosphazene matrix. The degree of permeability can be regulated by the size of the polyion that is used in the coating process. The percent release from microspheres crosslinked with poly-L-lysines ranging in molecular weight from 12 to 295 KDa is shown in Figure 5. As the molecular weight of the poly-L-lysine increases, the permeability of the coating increases, resulting in an increased release of 20 nm polystyrene beads from the microsphere. ;The ability to vary the polyphosphazene concentration in the microspheres, alter the side chains on the polymer and ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;-32- ;PCT/US94/07749 ;coat microspheres with poly-L-lysine makes it possible to formulate microspheres that will release antigens with pulsatile and/or sustained release kinetics. The manipulability of this polymer system combined with the very gentle conditions for gelation and microsphere formation make this polymer system particularly desirable for developing single dose vaccines which may elicit both antibody and cellular immune responses. ;Example 3: Efficacy of Influenza vaccine encapsulated in alginate administered orally to mice as measured by In vitro and in vivo immune response studies. ;Microencapsulated antigens were used to immunize mice by the oral route. The kinetics of the immune response were first determined by in vitro assays for humoral immunity. The use of in vivo studies allows determination of the capacity to effect antibody class switching, the effect of dose and route of immunization on the rapidity, amplitude and duration of the immune response, and the need for boosting the immune response. ELISA was used to evaluate total antigen specific responses as well as subclasses of IgG response, as described below. CTL assays could be performed to evaluate the cell mediated responses. ;As described in detail below, tetanus toxoid (Connaught Laboratories) and influenza virus were encapsulated for the immunogenicity studies. Microencapsulated antigens were prepared and quantitated as described above. The antigen concentration in alginate and polyphosphazene microspheres as determined by SDS-PAGE Was adjusted with sterile deionized water before administration. ;Female 7 to 8 week old BALB/c mice were randomized into groups of five. Thirty micrograms of flu antigen were administered orally by intubation. Blood samples were taken from the retroorbital sinus of C02 anaesthetized mice. Mice were euthanized with C02 in an inhalation chamber. ;SUBSTITUTE SHEET (RULE 26) ;PCT/US94/07749 ;33- ;The influenza mouse disease model system developed by Novak at al., Vaccine, 11:55-60 (1992), could be used to study the protection afforded by immunization with microencapsulated influenza. Mice are challenged at various times after immunization and the levels of virus replication in various organs determined. Although in previous studies parenteral immunization did not completely protect the nose and trachea, it does completely protect against virus propagation in the lungs. Thus, vaccine efficacy can be evaluated on the basis of the level of virus replication in the lungs. ;Influenza was grown in eggs according to standard methods and quantitated by protein, hemagglutination and plaque assays. Influenza was formalin inactivated by the addition of a 38% formaldehyde solution at a final dilution of 1:4000. Virus infectivity was also inactivated by exposure to gamma irradiation from a ^Co source to 1.2 x 106 rad. ;Anti-influenza specific antibodies in mouse serum were determined by ELISA in 96-well microtiter plates coated with 10 jig/ml of influenza infected MDCK cell lysate in sodium carbonate buffer pH 9.6. Sites available for non-specific binding of protein after coating and washing were blocked by adding 2.5% BSA in PBS solution. After blocking and washing, two-fold serial dilutions of sera in 1% BSA/PBS were added to the wells. Unbound serum was washed away and horseradish peroxidase-labelled goat anti-mouse IgG added. Unbound conjugate was washed away and serum antibody detected by adding the substrate o-phenylenediamine dihydrochloride. The reaction was stopped by the addition of 2M H2S04 and the absorbance read at 490 nm. The endpoint titers are the reciprocal of the greatest sample ' dilution producing a signal significantly greater than that of an antibody negative sample at the same dilution. ;The IgG isotypes of the ELISA reactive influenza specific antibodies were determined by the detection of murine antibodies bound to the antigens. Horseradish peroxidase ;WO 95/02416 ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;-34- ;labelled sheep anti-mouse antibody specific for mouse IgG subclasses 1, 2a, 2b and 3 was reacted with the mouse antibodies bound to the antigen in the ELISA plates. ;The influenza hemagglutination inhibition antibody assay was done with heat-inactivated mouse serum that had been incubated for 30 minutes with 10% chicken red blood cells to remove non-specific inhibitors. Twofold dilutions of sera were added to a 96 well microtiter plate and 8 HA units of virus suspension in an equal volume were added to each well and incubated at room temperature for 30 minutes. A 0.5% suspension of chicken red blood cells was added to each well and incubated at room temperature for 45-60 minutes. The HI titers are expressed as the reciprocal of the highest dilution that completely inhibits hemagglutination of erythrocytes. ;In the first group of studies, five groups of BALB/c mice, consisting of two mice per group, were immunized by oral intubation with sterile deionized water (Group I), empty alginate microspheres (Group II), alginate microspheres containing 30 pg Influenza (Group III), alginate microspheres containing 30 }jg Influenza plus 10 pg cholera toxin (CT) admixed (Group IV), or 30 fjg soluble Influenza (Group V). Blood and fecal samples were collected on days 7, 14, 21 and 28 post-immunization and the class specificity of influenza antibody reactivity was determined. ;Animals were immunized as described above with influenza antigen encapsulated in alginate, alone or in combination with cholera toxin. ;The results with alginate encapsulated influenza antigen are shown in Figures 6a, 6b, and 6c. Control mice that received no influenza antigen (groups I and II) showed no flu-specific serum IgM or IgG responses. Soluble influenza (Group V) induced a low IgM titer at day 7 that persisted at least through day 14 but there was no detectable IgG response, as shown in Figure 6a. Encapsulated flu together with CT induced high levels of flu-specific IgG at day 14 post-immunization, as shown in ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;Figure 6b. These levels were maintained up to day 28. Alginate encapsulated flu alone induced flu-specific IgG titers that were equivalent to those seen in the animals that received the microsphere influenza-CT admixture, as shown in Figure 6c. Good antibody titers were observed as early as 14 days, with high titers of IgG present through at least 77 days. ;Animals immunized with alginate encapsulated influenza plus cholera toxin were boosted at 35 days post primary immunization. The results are shown in Figure 7. Boosting with influenza in combination with cholera toxin elicits production of IgA, as measured in the fecal samples. ;In summary, the alginate encapsulated flu did not require the mucosal adjuvant CT for the induction of antigen specific IgM and IgG in the sera. The results obtained with alginate encapsulated influenza show that a single oral dose in the absence of CT elicits high flu specific serum IgG responses. Results in Figure 7 show that IgA antibodies are induced following a single oral boost with influenza encapsulated in alginate with CT. ;Example 4: Production of Antibody by oral administration of Influenza vaccine encapsulated in polyphosphazene to mice as measured by In vitro and in vivo immune response studies. ;The same protocol was followed for immunization of animals with influenza alone or in combination with cholera toxin, encapsulated in polyphosphazene microspheres, as described above. ;The results are shown in Figure 8. In the absence of cholera toxin there is no production of anti-influenza antibodies measurable in either the serum or the feces. With the combination of influenza antigen and cholera toxin there is production of IgM in a similar manner to that demonstrated with alginate encapsulated antigen (Figure 6b), although slightly delayed in onset. ;Example 5: Intranasal immunization of mice with microencapsulated tetanus toxoid. ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 ;PCT/US94/07749 ;-36- ;Mice were divided into four groups and inoculated intranasally with (1) tetanus toxoid in water (9 animals); (2) tetanus toxoid in alginate microspheres (9 animals); (3) tetanus toxoid in PCPP microspheres (10 animals); and (4) tetanus toxoid in microspheres consisting of 95% alginate/5% PCPP (9 animals). In each case 50 jjg of antigen was administered. Mice were assayed by ELISA for antibody production after two weeks (serum) and three weeks (bronchial and nasal washes). The results are shown in Table 1. ;administration of antigen in a polyphosphazene or alginate/polyphosphazene microsphere induces a serum IgG response. Moreover, the results demonstrate that this method of administration can be used to elicit production of IgA molecules, when the antigen is encapsulated within the combination of alginate and PCPP. ;Table 1: Intranasal inoculation with microencapsulated tetanus toxoid. ;Group/Animal treatmentanti-tetanus toxoid titer (log2) ;These results clearly demonstrate that intranasal ;IgG IgA ;1 ;2 ;5 ;4 ;3 ;7 ;8 ;9 ;6 ;tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid tetanus toxoid ;<256(<8) <256(<8) <256(<8) <256(<8) <256(<8) 256( 8) 256( 8) <256(<8) <256(<8) ;10 tetanus toxoid in alginate microspheres <256(<8) ;11 tetanus toxoid in alginate microspheres <256(<8) ;WO 95/02416 PCT/US94/07749 ;-37- ;12 ;tetanus toxoid in alginate microspheres ;<256(<8) ;13 ;tetanus toxoid in alginate microspheres ;<256(<8) ;14 ;tetanus toxoid in alginate microspheres ;<256(<8) ;15 ;tetanus toxoid in alginate microspheres ;<256(<8) ;16 ;tetanus toxoid in alginate microspheres ;<256(<8) ;17 ;tetanus toxoid in alginate microspheres ;<256(<8) ;18 ;tetanus toxoid in alginate microspheres ;<256(<8) ;19 ;tetanus toxoid in ;PCPP microspheres ;512(9) ;<2 (< ;1) ;20 ;tetanus toxoid in ;PCPP microspheres ;2048(11) ;<2 (< ;1) ;21 ;tetanus toxoid in ;PCPP microspheres ;512(9) ;<2 (< ;1) ;22 ;tetanus toxoid in ;PCPP microspheres ;512(9) ;23 ;tetanus toxoid in ;PCPP microspheres ;2048(11) ;24 ;tetanus toxoid in ;PCPP microspheres ;512( 9) ;25 ;tetanus toxoid in ;PCPP microspheres ;1024(10) ;26 ;tetanus toxoid in ;PCPP microspheres ;1024(10) ;27 ;tetanus toxoid in ;PCPP microspheres ;1024(10) ;28 ;tetanus toxoid in ;PCPP microspheres ;512(9) ;29 ;tetanus toxoid in ;Alginate/5% PCPP ms ;4096(12) ;8(3) ;30 ;tetanus toxoid in ;Alginate/5% PCPP ms ;4096(12) ;32(5) ;31 ;tetanus toxoid in ;Alginate/5% PCPP ms ;512(9) ;8(3) ;32 ;tetanus toxoid in ;Alginate/5% PCPP ms ;256(<8) ;33 ;tetanus toxoid in ;Alginate/5% PCPP ms ;2048(11) ;34 ;tetanus toxoid in ;Alginate/5% PCPP ms ;2048(11) ;35 ;tetanus toxoid in ;Alginate/5% PCPP ms ;2048(11) ;36 ;tetanus toxoid in ;Alginate/5% PCPP ms ;2048(11) ;37 tetanus toxoid in Alginate/5% PCPP ms 1024(10) ;Example 6: Parenteral immunization of mice with tetanus toxoid encapsulated in microspheres and comparison with immunization with conventional adjuvants. ;Traditionally, most injected non-replicating vaccines have required multiple doses to achieve sufficient serum antibody titers to be protective. For obvious reasons, it would be much more desirable to achieve protection with a single inoculation. ;\ ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;-38- ;Therefore, the effect of polyphosphazene on the immunogenicity of antigens was examined in mice that were immunized subcutaneously with a single dose. Antigen formulated in water, alum and complete Freund's adjuvant was included in many experiments as a comparator. ;The immunogenicity of tetanus toxoid antigen formulated in polymeric microspheres composed of alginate or polyphosphazene was compared to soluble tetanus toxoid and tetanus toxoid in the standard adjuvants, alum and complete Freund's adjuvant (CFA). Groups of five mice were immunized by the subcutaneous route with 20 pg of tetanus toxoid. ;The results are shown in Table 2. The anti-tetanus toxoid serum immune responses were assayed by ELISA. Soluble tetanus toxoid antigen and alginate microencapsulated tetanus toxoid induced a maximum titer of 512 by week 13. ;Polyphosphazene microspheres containing tetanus toxoid induced higher antibody titers at earlier times post immunization than alum or complete Freund's adjuvanted tetanus toxoid. ;Furthermore, polyphosphazene microspheres containing tetanus toxoid induced antibody tiers that were still rising at 13 weeks post immunization. At this late time point, tetanus toxoid in polyphosphazene microspheres had elicited a titer of 65,536, ;which was approximately 100 times as strong a response as seen for soluble tetanus toxoid and as good as or slightly better (two to four fold higher) than was seen for alum and complete Freund's adjuvant. Polyphosphazene microspheres were clearly superior to alginate microspheres in the induction of antibodies to tetanus toxoid. ;SUBSTITUTE SHEET (RULE 26) ;WO 95/02416 PCT/US94/07749 ;-39- ;Table 2: ELISA Titers in Mice Inoculated SC with Tetanus Toxoid anti TT ELISA titer ;week 3 ;week 5 ;week 7 ;week 9 ;week 13 ;TT in Water ;<256 ;256 ;256 ;256 ;512 ;TT in Alginate MS ;256 ;512 ;512 ;512 ;512 ;TT in Alum ;2048 ;8192 ;16384 ;32768 ;32768 ;TT in CFA ;2048 ;16384 ;16384 ;32768 ;16384 ;TT in Polyphosphazene MS ;8192 ;16384 ;32768 ;32768 ;65536 ;The dose dependent effect of immunization with tetanus toxoid was examined by immunizing mice with varying amounts of tetanus toxoid formulated into polyphosphazene microspheres or complete Freund's adjuvant. ;The results are shown in Table 3. The immunogenicity of tetanus toxoid in polyphosphazene microspheres compared very favorably with complete Freund's adjuvant formulated tetanus toxoid. At all time points and tetanus toxoid doses, the ELISA titers for the two formulations were within a two-fold dilution of each other. ;SUBSTITUTE SHEET (RULE 26) ;CO ;cz ;00 CO ;-H rn ;CO ;nz m q ;Z33 CZ I— ;m ro cx> ;Table 3: TT Antibodies that neutralize influenza infectivity were assayed in a 50% plaque reduction assay. Flu in polyphosphazene microspheres induced a detectable titer of 800 by week 13, whereas, flu in water and complete Freund's adjuvant did not elicit detectable neutralizing antibody titers. The HAI and neutralization assays are sensitive functional antibody assays for influenza. Thus, the immune response engendered by polyphosphazene microspheres is superior to complete Freund's adjuvant.
SUBSTITUTE SHEET (RULE 26) Table 6: Influenza Plaque Reduction Assay week 13 Flu in Polyphosphazene MS 800 Flu in Polyphosphazene MS Flu in Water Flu in CFA Normal mouse serum <200 <200 <200 The IgG isotypes of the antibodies induced by these formulations were determined by an ELISA assay. The results are shown in Table 7. Alum adjuvanted influenza elicited a purely IgGl response as expected. Flu formulated in Complete Freund's Adjuvant induced mostly an IgGl response that peaked by week 7 and was waning by week 13. Flu formulated in alginate and polyphosphazene microspheres also induced largely an IgGl response that by week 7 was higher than flu formulated in alum. Again, polyphosphazene microsphere formulated antigen induced titers that compared very favorably with those induced by complete Freund's adjuvant formulated antigen. Polyphosphazene microspheres like complete Freund's adjuvant was able to induce significant levels of IgG2a and IgG2b antibodies. A significant difference in the immune response was found in the level of activity detected in the IgG3 isotype. Polyphosphazene microspheres were the only formulation able to induce a significant IgG3 antibody titer.
Table 7: Flu ELISA Isotyping Results 3 weeks 7 weeks 13 weeks IgGl IaG2A IaG2B IqG3 IgGl IaG2A IgG2B IaG3 IaGl IaG2A IaG2B IgG3 Flu in algina te MS 1024 <256 256 <256 65536 1024 512 <256 8192 512 <256 <256 Flu in PPP MS 8192 4096 512 512 131072 16384 1024 4096 16384 16384 2048 1024 Flu in Alum 512 <256 <256 <256 16384 <256 <256 <256 8192 <256 <256 <256 Flu in CFA 8192 1024 4096 <256 >52428 8192 4096 <256 32768 2048 2048 <256 Flu in Water 256 512 256 <256 2048 1024 256 <256 1024 512 <256 <256 WO 95/02416 PCT/US94/07749 Modifications and variations of the present invention, polymer adjuvants and methods of synthesis and use in vaccine compositions, will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.
SUBSTITUTE SHEET (RULE 26}
Claims (41)
1. A vaccine composition comprising hydrogel microparticles formed of one or more biocompatible polymers encapsulating an amount of an antigen effective to elicit an immunogenic response, wherein the microparticles have a diameter of 200 microns or less. ——
2. The composition of claim 1 wherein thrp micropartic^s"1^. W:.-' ■ • '• ■ have a diameter of between one micron and fifteen-microns.
3. The composition of claim 1 wherein the polymer is 'WtJii biocompatible polymer selected from the group consisting of. — — polymers and salts of polymers that can be crosslinked by \ physical crosslinking, covalent crosslinking or -ionic crosslinking to form a hydrogel.
4. The composition of claim 3 wherein the polymer is selected from the group consisting of alginate, gelatin, pectin, collagen, phosphazene polyelectrolytes, poly(acrylamide), poly(methacrylamide), poly(vinyl acetate), poly(N-vinyl pyrrolidone), poly(hydroxyethylmethacrylate), poly(ethylene glycol), poly(vinyl alcohols), poly(acrylic acids), poly(methacrylie acids), sulfonated polystyrene, polyamines, poly(vinylpyridine), and mixtures thereof.
5. The composition of claim 3 wherein the polymer is a phosphazene polyelectrolyte of the formula A a wherein A and B can vary independently in the polymer, and can be: (i) a group that is susceptible to hydrolysis under the conditions of use; or 2.69 A ' -47- 9 ^ ^ (ii) a group that is not susceptible to hydrolysis under the conditions of use selected from the group consisting of aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, heteroalkyl, (aliphatic)amino-, heteroaralkyl, di(aliphatic)amino- arylamino-, diarylamino-, alkylarvlam-i-no-s-r'- -oxyphenylC02H, -oxyphenylS03H, -oxyphenylhydroxyl, -oxypheny 1P03h, -oxyaliphatic, \ ^ u - -oxyalkyl, -oxy(aliphatic) C02H, \ " 7 -oxy(aliphatic) SOjH, -oxy(aliphatic )P03H, i — -oxy(aliphatic)hydroxyl, -oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic, -thioalkaryl, thioaralkyl, or -NHC (0) 0- (aryl or aliphatic), -0-[ (CHjJ^ly-CH^^Hj, -0- [ (CH2) x0 ] yCH2) jNH (CH2) xS03H , and —0-[ (CH2)x0]y-(aryl or aliphatic), wherein x is 1-8 and y is an integer of 1 to 20; and wherein n between 10 and 20,000.
6. The composition of claim 1 wherein the polymer is cross-linked with a multivalent cation or polyelectrolyte.
7. The composition of claim 4 wherein the polymer is a mixture of alginate and phosphazene polyelectrolyte.
8. The composition of claim 1 wherein the antigen is selected from the group consisting of compounds derived from cells, bacteria, virus particles, and portions thereof, wherein the compound is selected from the group consisting of proteins, peptides, polysaccharides, glycoproteins, glycolipids, nucleic acid, and combinations thereof.
9. The composition of claim 8 wherein the antigen is derived from an organism selected from the group consisting of rotavirus, measles, mumps, rubella, polio, hepatitis A and B and herpes viruses, human immunodeficiency virus, Haemophilus influenza, Clostridium tetani, influenza, Corynebacterium diphtheria, and Neisseria gonorrhea. oxyaryl, fr'M ^'69~Cf -48-
10. The composition of claim 1 wherein the polymer is covalently conjugated with the antigen.
11. The composition of claim 1 further comprising an adjuvant from the group consisting of muramyl dipeptides, muramyl tripeptide, cytokines, diphtheria toxin, exotoxin A, cholera toxin-A, cholera toxin-B, and soluble phosphazene polyelectrolyte.
12. The composition of claim 1 wherein the microparticles are within a coating protecting the microparticles from the acid pH of the_stomach.
13. Use of hydrogel microparticles for the preparation of a vaccine for mucosal administration to elicit an immune response wherein said microparticles comprise a polyphosphazene polymer and said microparticles contain an amount of an antigen effective to elicit an immune response, wherein the microparticles are 200 microns or less in diameter.
14. The use of claim 13 wherein the microspheres aretobe administered to mucosal surfaces.
15. The use of claim 14 wherein the route to the mucosal surfaces is to be intratracheal, i
16. The use of claim 14 wherein the route to the mucosal surfaces is to be intranasal.L
17. The . use of claim 14 wherein the mucosal surfaces is selected from the group consisting of rectal and vaginal.
18. The use of claim 14 wherein the route to the mucosal surfaces is to be orally. INTELLECTUAL PROPERTY OFFICE OF N.Z. " 5 FEB 2001 [RECEIVED ■'/V .■ /v^ ! i! 4 /i /, t-l. -49-
19. The : use of claim 13 wherein the microparticles have a diameter of between one micron and fifteen microns.
20. The use of claim 13 wherein the antigen is selected from the group consisting of compounds derived from cells, bacteria, and virus particles, wherein the compound is selected from the group consisting of proteins, peptides, polysaccharides, glycoproteins, glycolipids, and nucleic acids.
21. The use of claim 20 wherein the antigen is derived from an organism selected from the group consisting of rotavirus, measles, mumps, rubella, polio, hepatitis A and B, herpes viruses, Haemophilus influenza, Clostridium tetani, influenza, Corynebacterius diphtheria, and Neisseria gonorrhea.
22. The use of claim 13 wherein the polymer is covalently conjugated with the antigen.
23. The use - of claim 13 wherein the microparticles are to be administered in combination with a material protecting the microparticles from the acid pH of the stomach.
24. The use of claim 13 wherein the microparticles have different release rates.
25. The use of claim 13 wherein the polyphosphazene polymer is a crosslinked polyphosphazene.
26. The use of claim 25 wherein the polymer is ionically crosslinked.
27. The use ' of claim 13 wherein the polyphosphazene is biodegradable.
28. The use of claim 13 wherein the microparticles comprise polyphosphazene and alginate.
29. The use of claim 13 wherein the polyphosphazene contains carboxylatophenoxy pendant groups. INTELLECTUAL PROPERTY OFFICE OF N.Z. - 5 FEB 2001 iECEBVEO -50-
30. The use of claim 13 wherein the polyphosphazene is a copolymer which comprises poly[di(carboxylatophenoxy)] phosphazene.
31. The use of claim 13 wherein the polyphosphazene polymer is poly[di(carboxylatophenoxy)phosphazene-co- di(chloro)phosphazene-co-(carboxylatophenoxy)(chloro-)phosphazene].
32. The use of claim 13 wherein the polyphosphazene is poly[dicarboxylatophenoxy phosphazene].
33. A method for making a vaccine composition comprising forming microparticles having a diameter of 200 microns or less by forming a hydrogel of one or more biocompatible polymers in the presence of an antigen.
34. The method of claim 33 wherein the polymer is formed into a hydrogel by physical crosslinking, covalent crosslinking or ionic crosslinking.
35. The method of claim 34 wherein the polymer is selected from the group consisting of alginate, gelatin, pectin, collagen, phosphazene polyelectrolytes, poly(acrylamide), poly(methacrylamide), poly(vinyl acetate), poly(N-vinyl pyrrolidone), poly(hydroxyethylmethacrylate), poly(ethylene INTELLECTUAL PROPERTY OFFICE OF N.Z. ~ 5 FEB 2001 - f -51- 2^9 k glycol), poly(vinyl alcohols), poly(acrylic acids), poly(methacrylic acids), sulfonated polystyrene, polyamines, poly(vinylpyridine), and mixtures thereof.
36. The method of claim 35 wherein the polymer is a phosphazene polyelectrol wherein A and B can vary independently in the polymer, and can be: (i) a group that is susceptible to hydrolysis under the conditions of use; or conditions of use selected from the group consisting of aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, heteroalkyl, (aliphatic)amino-, heteroaralkyl, di(aliphatic)amino- arylamino-, diarylamino-, alkylarylamino-, -oxyaryl, -oxyphenylC02H, -oxyphenylS03H, -oxyphenylhydroxyl, -oxypheny1P03H, -oxyaliphatic, -oxyalkyl, -oxy(aliphatic)C02H, -oxy(aliphatic) S03H, -oxy(aliphatic)P03H, -oxy(aliphatic)hydroxyl, -oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic, -thioalkaryl, thioaralkyl, or - NHC (0) 0— (aryl or aliphatic), -0-[ (CHj^Ojy-CH^^Hj, -0- [ (CH2) x0 ] yCH2) jNH (CH2) xS03H , and —0—[(CH2)x0]y— (aryl or aliphatic), wherein x is 1-8 and y is an integer of 1 to 20; and wherein n between 10 and 20,000. (ii) a group that is not susceptible to hydrolysis under the 2.6 9 O -52-
37. The method of claim 33 further comprising selecting polymers having a specific molecular weight to achieve a controlled rate of release of the antigen.
38. The method of claim 33 further comprising selecting the crosslinking cation or polymer molecule having a particular molecular weight to achieve a controlled rate of release of the antigen.
39. The method of claim 33 further comprising selecting the polymer with a hydrolysis-sensitive pendant group to increase the degradation rate in an aqueous environment.
40. The method of claim 33 further comprising mixing microparticles containing antigen which have different release rates together to form an immunogenic composition having pulsed release.
41. The method of claim 33 further comprising mixing microparticles containing antigen which have different release rates together to form an immunogenic composition having extended release over a period of time due to release of antigen from some microparticles occurring after a longer period of time than other microparticles.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/090,841 US5562909A (en) | 1993-07-12 | 1993-07-12 | Phosphazene polyelectrolytes as immunoadjuvants |
US08/147,781 US5529777A (en) | 1993-07-12 | 1993-11-04 | Hydrogel microencapsulated vaccines |
PCT/US1994/007749 WO1995002416A1 (en) | 1993-07-12 | 1994-07-11 | Hydrogel microencapsulated vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ269411A true NZ269411A (en) | 2001-03-30 |
Family
ID=26782696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ269411A NZ269411A (en) | 1993-07-12 | 1994-07-11 | Hydrogel microencapsulated vaccines containing antigens |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0792161A4 (en) |
JP (1) | JPH09500132A (en) |
CN (1) | CN1128953A (en) |
AU (1) | AU690567B2 (en) |
BR (1) | BR9407397A (en) |
CA (1) | CA2167081A1 (en) |
NZ (1) | NZ269411A (en) |
WO (1) | WO1995002416A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM572294A0 (en) * | 1994-05-18 | 1994-06-09 | Vaccine Technologies Pty. Ltd. | Delivery vehicle for bioactive molecule |
US5674495A (en) * | 1995-02-27 | 1997-10-07 | Purdue Research Foundation | Alginate-based vaccine compositions |
US5879712A (en) * | 1995-06-07 | 1999-03-09 | Sri International | Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced |
US5807757A (en) * | 1996-07-02 | 1998-09-15 | Virus Research Institute, Inc. | Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation |
US5980948A (en) * | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
AU7563798A (en) * | 1997-04-30 | 1998-11-24 | Emory University | Methods and compositions for administering dna to mucosal surfaces |
CA2312839C (en) * | 1997-12-02 | 2008-01-15 | Lisbeth Illum | Compositions for nasal administration |
US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
AU2001261433A1 (en) | 2000-05-12 | 2001-11-26 | Pharmacia And Upjohn Company | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
US20040131631A1 (en) * | 2002-11-22 | 2004-07-08 | Alexander Andrianov | Polyphosphazene immunostimulants |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
JP2006517523A (en) | 2003-01-17 | 2006-07-27 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | Injectable hydrogel microspheres from aqueous two-phase systems |
CN101090710B (en) * | 2004-10-25 | 2012-03-14 | 宝利策尼克斯有限公司 | Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
KR100784485B1 (en) | 2006-01-18 | 2007-12-11 | 한국과학기술연구원 | Biodegradable and thermosensitive polyorganophosphazene hydrogel, preparation method thereof and use thereof |
EP1985284A1 (en) * | 2007-04-25 | 2008-10-29 | OctoPlus Sciences B.V. | Vaccine formulation |
WO2008100142A2 (en) * | 2007-02-12 | 2008-08-21 | Octoplus Sciences B.V. | Vaccine formulation |
EP2196196A1 (en) * | 2008-12-10 | 2010-06-16 | Medipol S.A. | Compound, medicament, vaccine composition and nanocapsules |
US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
GB201212010D0 (en) * | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
WO2015084594A1 (en) | 2013-12-06 | 2015-06-11 | Advanced Bionutrition Corporation | Composition for oral delivery of bioactive agents |
WO2017075483A1 (en) * | 2015-10-28 | 2017-05-04 | University Of Maryland, College Park | Multifunctional biodegradable carriers for drug delivery |
CN105214100A (en) * | 2015-11-16 | 2016-01-06 | 中国医学科学院生物医学工程研究所 | A kind of pH response microcapsule-type protein vaccine carrier and preparation method |
CN112618709B (en) * | 2019-09-24 | 2023-11-03 | 华南理工大学 | Pig oral vaccination slow-release adjuvant and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880622A (en) * | 1986-05-20 | 1989-11-14 | Research Corporation Technologies, Inc. | Water-soluble phosphazene polymers having pharmacological applications |
GB8826116D0 (en) * | 1988-11-08 | 1988-12-14 | Danbiosyst Ltd | Adhesive drug delivery composition |
US5032405A (en) * | 1989-09-27 | 1991-07-16 | Warner-Lambert Company | Oral pharmaceutical composition for acid sensitive proteinaceous agents |
US5149543A (en) * | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
-
1994
- 1994-07-11 CA CA002167081A patent/CA2167081A1/en not_active Abandoned
- 1994-07-11 CN CN94193066A patent/CN1128953A/en active Pending
- 1994-07-11 NZ NZ269411A patent/NZ269411A/en unknown
- 1994-07-11 BR BR9407397A patent/BR9407397A/en not_active Application Discontinuation
- 1994-07-11 WO PCT/US1994/007749 patent/WO1995002416A1/en not_active Application Discontinuation
- 1994-07-11 EP EP94923417A patent/EP0792161A4/en not_active Withdrawn
- 1994-07-11 AU AU73286/94A patent/AU690567B2/en not_active Ceased
- 1994-07-11 JP JP7504650A patent/JPH09500132A/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU690567B2 (en) | 1998-04-30 |
BR9407397A (en) | 1996-11-05 |
CN1128953A (en) | 1996-08-14 |
CA2167081A1 (en) | 1995-01-26 |
EP0792161A1 (en) | 1997-09-03 |
JPH09500132A (en) | 1997-01-07 |
AU7328694A (en) | 1995-02-13 |
EP0792161A4 (en) | 1998-04-29 |
WO1995002416A1 (en) | 1995-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5529777A (en) | Hydrogel microencapsulated vaccines | |
AU690567B2 (en) | Hydrogel microencapsulated vaccines | |
WO1995002416A9 (en) | Hydrogel microencapsulated vaccines | |
Payne et al. | Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery | |
US6287604B1 (en) | Biodegradable targetable microparticle delivery system | |
US6207171B1 (en) | Polyphosphazene microspheres | |
Andrianov et al. | Protein release from polyphosphazene matrices | |
JP2739570B2 (en) | Single injection vaccine dosage form | |
JPH03503892A (en) | Methods and compositions for enhancing immune responses | |
US20060292181A1 (en) | Method for Inducing a Cell-Mediated Immune Response and Improved Parenteral Vaccine Formulations Thereof | |
JP2008530347A (en) | Immunostimulatory polyphosphazene compounds | |
Hanes et al. | Polymer microspheres for vaccine delivery | |
AU2003205106A8 (en) | Pace-a microspheres for delivery of antigens | |
CA2731995C (en) | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor | |
WO2001015727A2 (en) | Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof | |
WO1994021289A1 (en) | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |